Alkermes Plc Hits New 52-Week High of $45.36, Up 81.23%

Alkermes Plc has reached a significant milestone by hitting a new 52-week high of USD 45.36 on June 10, 2026. This achievement underscores the company's strong performance in the Pharmaceuticals & Biotechnology sector, where it has demonstrated a remarkable one-year performance of 81.23%, significantly outpacing the S&P 500's 20.34% during the same period. With a market capitalization of USD 5,008 million, Alkermes is classified as a small-cap company. The stock's price-to-earnings (P/E) ratio stands at 21.00, reflecting its valuation relative to earnings. Additionally, the company maintains a return on equity of 13.28%, indicating effective management of shareholder equity. Alkermes also has a price-to-book ratio of 2.75, which provides insight into its market valuation compared to its book value. Despite a dividend yield of 0.00% and a negative debt-to-equity ratio of -0.72, the recent price movement highlights Alkermes' position in the market and its potential resilience in the competitive landscape of the pharmaceuticals and biotechnology industry.